Lupin launches Prucalopride Tablets in United States

26 Jun 2025 Evaluate

Lupin has launched Prucalopride Tablets, 1 mg, and 2 mg, in the United States (U.S.), following the recent approval of its Abbreviated New Drug Application (ANDA) from United States Food and Drug Administration (USFDA). 

Prucalopride Tablets are bioequivalent to Motegrity tablets, 1 mg and 2 mg, of Takeda Pharmaceuticals U.S.A. Inc., and indicated for the treatment of chronic idiopathic constipation (CIC) in adults. Prucalopride Tablets, 1 mg, and 2 mg (RLD Motegrity) had estimated annual sales of $184 million in the U.S. (IQVIA MAT April 2025).

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2105.85 2.55 (0.12%)
02-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1729.35
Dr. Reddys Lab 1255.45
Cipla 1510.95
Zydus Lifesciences 916.50
Lupin 2105.85
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×